Nuvation Bio Inc.
NUVB
Jodie situation report
Nuvation Bio Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- NUVB's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NUVB's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind NUVB
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
IVBXFFiling-linked namepartnerMar 2, 2026 ▾
“Taletrectinib is being commercialized in Japan by our partner NK under the brand name IBTROZI and in China by our partner Innovent under the brand name DOVBLERON®.”
AZNAstraZeneca PLCcompetitorMar 2, 2026 ▾
“There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company (“BMS”), Eli Lilly, Merck, Novartis Phar…”
NUVLNuvalent InccompetitorMar 2, 2026 ▾
“Other ROS1 inhibitors currently in clinical-stage development include Nuvalent’s zidesamtinib.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NUVB is currently a Follower in the organic co-movement group Biotech and Materials. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for NUVB; it is not active in the latest market snapshot.